Compare Liberty Global Ltd Class C (LBTYK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs GeneDx Holdings Corp — how do they compare? Liberty Global Ltd Class C trades at $8.5 (market cap $3.06B), while GeneDx Holdings Corp trades at $67.69 (market cap $2.02B). The key difference: Liberty Global Ltd Class C is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and GeneDx Holdings Corp for 19 Days on average.
| LBTYK | WGS | |
|---|---|---|
Market Cap | $3.06B | $2.02B |
Volume | 2,508,956 | 734,640 |
Sector | Media | Health |
52-Week High | $12.67 | $167.51 |
52-Week Low | $8.75 | $34.51 |
Typical Hold Time | 21 Days | 19 Days |
Enterprise Value | $9.72B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
